Management of POF is confined to relief of menopausal symptoms, prevention and treatment of postmenopausal osteoporosis, and the infertility problem. Many therapies are now present and they include HRT, alternative and complementary therapies, and the recent modalities now used to prevent and treat postmenopausal osteoporosis. All women with POF should be encouraged to take HRT until age 50 years to relieve the symptoms of estrogen deficiency. Strontium ranelate (Protelos) is the first antiosteoporotic treatment to simultaneously increase bone formation and decrease bone resorption. Only IVF and embryo transfer using donor oocytes has demonstrated high success rates. There are several potential uses of cryopreserved ovarian tissue. Using present techniques, ischemic injury to the transplanted tissue results in the loss of the entire growing follicle population. Research should focus on refining cryopreservation protocols, and transplantation techniques that decrease ischemia